The Online Investor
Spectrum Pharmaceuticals Inc (SPPI)

Spectrum Pharmaceuticals is a commercial-stage biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has one commercial asset, ROLVEDON™, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as one drug candidate in late-stage development, Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations.
Company Name: 
Spectrum Pharmaceuticals Inc
Stock buyback: 
SPPI buyback
Website: 
www.sppirx.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree SPPI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
SPPI Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Spectrum Pharmaceuticals Inc (SPPI) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.